Finance News

Boston Scientific Prices $1.0 Billion of Senior Notes

3.2 from 4 votes
Friday, February 23, 2018

MARLBOROUGH, Mass. - Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.0 billion aggregate principal amount of its 4.000% senior notes due March 1, 2028 under the company's shelf registration statement.

The company expects to receive the net offering proceeds upon closing on February 26, 2018, subject to customary closing conditions. Boston Scientific intends to use the net proceeds from the offering to redeem its 2.650% notes due October 2018, of which $600 million aggregate principal amount was outstanding as of the date hereof, and to repay short term debt and to pay related fees, expenses and premiums. Any such redemption would be made in accordance with the terms of the applicable indenture, including providing the required notice of redemption.

Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. The offering is being made by means of a prospectus and related preliminary prospectus supplement only, copies of which or information concerning this offering may be obtained by contacting the joint book-running managers: Barclays Capital Inc., toll-free at (888) 603-5847; Citigroup Global Markets Inc., toll-free at (800) 831-9146, or Merrill Lynch, Pierce, Fenner & Smith Incorporated, toll free at (800) 294-1322.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

Kate Haranis
Phone: 508-683-6585

Source: Boston Scientific Corporation
3.2 from 4 votes
Free Newsletter